Oncology (all articles)
Review | Lung cancer screening: new evidence, updated guidance
26 Jan, 2023 | 12:08h | UTCLung cancer screening: New evidence, updated guidance – Journal of Family Practice
Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years
26 Jan, 2023 | 12:04h | UTC
Commentary from the author on Twitter
🚨Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer
— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022
RCT | Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion
26 Jan, 2023 | 12:03h | UTC
RCT | Preoperative chemotherapy reduced recurrence in operable colon cancer
25 Jan, 2023 | 11:29h | UTCEditorial: FOxTROT: Are We Ready to Dance? – Journal of Clinical Oncology
News Release: Chemotherapy before surgery cuts risk of colon cancer returning, trial finds – Cancer Research UK
Commentary: New treatment strategy cuts risk of bowel cancer returning by 28% – The Guardian
Commentary from one of the authors on Twitter (thread – click for more)
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)#crcsmhttps://t.co/y1hU6qWdXF— Jenny Seligmann (@JenSeligmann) January 20, 2023
Consensus Paper | Tumor surveillance guidelines for individuals with neurofibromatosis type 1
25 Jan, 2023 | 11:24h | UTC
Single-arm phase 2 study | Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors
24 Jan, 2023 | 14:19h | UTCNeoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors – The ASCO Post
RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla
24 Jan, 2023 | 14:15h | UTC
Commentary on Twitter
New & available #OpenAccess | Occurrence of breast-cancer–related #lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial https://t.co/fXB7PfysCH @OncoAlert pic.twitter.com/wWNhC9BMvY
— ACS Journal Cancer (@JournalCancer) October 20, 2022
Meta-analysis reaffirms benefits of O-RADS MRI for diagnosing indeterminate adnexal lesions
24 Jan, 2023 | 14:05h | UTCOriginal Study: O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates – Radiology (link to abstract – $ for full-text)
Commentary on Twitter
A meta-analysis of 4520 adnexal lesions from 12 studies showed that MRI O-RADS has a 92% summary sensitivity and a 91% summary specificity in characterizing lesions that are indeterminate at US. https://t.co/WSJVQUiM4T pic.twitter.com/kssAK2s02N
— Radiology (@radiology_rsna) November 23, 2022
AHA Statement | Cancer therapy-related hypertension
23 Jan, 2023 | 13:46h | UTCTop Things to Know: Cancer Therapy-Related HTN – American Heart Association
Cohort Study | Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy in 120 000 repeated screening colonoscopies
23 Jan, 2023 | 13:36h | UTCCommentaries:
Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay
Commentary on Twitter
Large registry-based study finds strong potential for risk-adapted #colorectalcancer screening, suggests extension of screening endoscopy intervals beyond 10 years may be warranted particularly in asymptomatic female and younger participants. https://t.co/fChg6DRyPw @DKFZ
— JAMA Internal Medicine (@JAMAInternalMed) January 17, 2023
Guideline | Management of metastatic castration-naive and castration-sensitive prostate cancer
23 Jan, 2023 | 13:33h | UTC2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer – Canadian Urological Association Journal (PDF here)
See also: Summary of changes (PDF here)
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Guideline for diagnosis, treatment and follow-up
23 Jan, 2023 | 13:32h | UTC
RCT | Adjuvant S-1 compared with observation in resected biliary tract cancer
23 Jan, 2023 | 13:24h | UTCAdjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Nakachi et al – Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial https://t.co/E6y7a9dWNf#gitwitter #biliarytractcancer #onctwitter @OncoAlert #JCOG pic.twitter.com/WEBFXjIWce
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 20, 2023
Single-arm phase 2 study | Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
23 Jan, 2023 | 13:22h | UTCFutibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg
— NEJM (@NEJM) January 19, 2023
Cohort Study | Hemicolectomy vs. appendectomy for patients with appendiceal neuroendocrine tumors 1–2 cm in size
23 Jan, 2023 | 13:21h | UTCHemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors – The ASCO Post
Trends and characteristics of potentially preventable emergency department visits among patients with cancer in the US
23 Jan, 2023 | 13:14h | UTCEditorial: Emergency Department Visits Among Patients With Cancer in the US – JAMA Network Open
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1616148487250247681
Cancer of unknown primary | ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
20 Jan, 2023 | 14:40h | UTCRelated:
MRI anatomy of the rectum: key concepts important for rectal cancer staging and treatment planning
20 Jan, 2023 | 14:34h | UTC
Single-arm phase 1-2 study | Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer
20 Jan, 2023 | 14:31h | UTCSotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a median progression-free survival of 4 months. https://t.co/BUepIWvx65 pic.twitter.com/i1kugfC6Nq
— NEJM (@NEJM) December 21, 2022
RCT | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer
20 Jan, 2023 | 14:20h | UTCAbemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Interim Analysis of Overall Survival in the monarchE Trial – The ASCO Post
Commentary on Twitter
https://twitter.com/DrYukselUrun/status/1600233075455143937
CanRisk-Prostate | A comprehensive, externally validated risk model for the prediction of future prostate cancer
20 Jan, 2023 | 14:22h | UTCCommentary: Risk Model for Predicting the Development of Prostate Cancer – The ASCO Post
News Release: Prostate cancer risk prediction algorithm could help target testing at men at greatest risk – University of Cambridge
RCT | Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer
20 Jan, 2023 | 14:19h | UTC
Commentary on Twitter
Single centre #RCT of surgery for T3/4 N+ #rectalcancer before or after 8 weeks of CRT
🧑🤝🧑350 patients
⚖️no difference locoregional recurrence
Distant mets more common in delayed group at 5yrs
DFS and OS similar#some4surgery @SEIQuirurgica @asgbi https://t.co/4evsKNKKK1 pic.twitter.com/CxI0GJdG56— BJS Open (@BjsOpen) October 24, 2022
Study shows patients with circulating tumor DNA are at increased risk of relapse after surgery for resectable colorectal cancer
19 Jan, 2023 | 14:18h | UTCCommentary: Data Support ctDNA as a Prognostic Marker for Recurrence/Benefit in Colorectal Cancer – Cancer Network
Commentary on Twitter
In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapyhttps://t.co/hKlRt1ZW6T
— Nature Medicine (@NatureMedicine) January 17, 2023
Consensus Paper | Management of early-onset colorectal cancer
19 Jan, 2023 | 14:14h | UTC
Guideline | Use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors
19 Jan, 2023 | 14:13h | UTC